General features of the study population
| Whole study population (n=346) | Hepato cohort (n=138) | Bariatric cohort (n=208) | |
|---|---|---|---|
| Demographic data | |||
| Age (years) | 53 (46–60) | 57 (51–63) | 50 (43–56) |
| Male sex (n (%)) | 138 (40) | 72 (52) | 66 (32) |
| Cohort origin (hepato/bariatric) (n (%)) | 138 (40)/208 (60) | − | − |
| Metabolic data | |||
| BMI (kg/m2) | 42 (32–49) | 31 (27–34) | 47 (42–54) |
| High blood pressure (n (%)) | 261 (76) | 109 (79) | 152 (73) |
| On statins (n (%)) | 154 (45) | 60 (44) | 94 (45) |
| On antidiabetic drugs (n (%)) | 292 (84) | 121 (88) | 171 (82) |
| Number of antidiabetic drugs | 2 (1–2) | 2 (1–2) | 2 (1–2) |
| Metformin (n (%)) | 256 (74) | 101 (73) | 155 (75) |
| Sulfonylureas (n (%)) | 113 (33) | 54 (39) | 59 (28) |
| Insulin (n (%)) | 84 (24) | 31 (23) | 53 (26) |
| Metabolic syndrome (IDF) (n (%)) | 312 (93) | 117 (89) | 195 (96) |
| Biochemical data | |||
| HbA1c (%) | 7.1 (6.5–8.1) | 7.1 (6.5–7.9) | 7.1 (6.6–8.2) |
| Triglyceridaemia (mmol/L) | 1.7 (1.2–2.5) | 1.7 (1.2–2.7) | 1.7 (1.1–2.4) |
| Total cholesterol (mmol/L) | 4.7 (4.1–5.4) | 4.8 (4.0–5.5) | 4.6 (4.1–5.4) |
| HDL cholesterol (mmol/L) | 1.1 (0.9–1.3) | 1.1 (0.9–1.3) | 1.1 (1.0–1.4) |
| AST (U/L) | 31 (24–46) | 40 (29–58) | 27 (22–38) |
| ALT (U/L) | 41 (27–62) | 55 (38–80) | 33 (23–49) |
| GGT (U/L) | 51 (32–90) | 65 (44–120) | 44 (29–70) |
| Histological data | |||
| NASH (n (%)) | 196 (57) | 84 (61) | 112 (54) |
| Significant fibrosis (F≥2) (n (%)) | 167 (48) | 79 (57) | 88 (42) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein cholesterol; IDF, International Diabetes Federation.